Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial

BACKGROUND: Long-term hormone therapy alone is standard care for metastatic or high-risk, non-metastatic prostate cancer. STAMPEDE—an international, open-label, randomised controlled trial—uses a novel multiarm, multistage design to assess whether the early additional use of one or two drugs (doceta...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: James, Nicholas D, Sydes, Matthew R, Mason, Malcolm D, Clarke, Noel W, Anderson, John, Dearnaley, David P, Dwyer, John, Jovic, Gordana, Ritchie, Alastair WS, Russell, J Martin, Sanders, Karen, Thalmann, George N, Bertelli, Gianfilippo, Birtle, Alison J, O'Sullivan, Joe M, Protheroe, Andrew, Sheehan, Denise, Srihari, Narayanan, Parmar, Mahesh KB
Natura: Artigo
Lingua:Inglês
Pubblicazione: Lancet Pub. Group 2012
Soggetti:
Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3398767/
https://ncbi.nlm.nih.gov/pubmed/22452894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(12)70088-8
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi